WO1994004533A1 - DERIVES D'INDOLE CONDENSES UTILISES COMME ANTAGONISTES DES RECEPTEURS 5HT2C et 5HT¿2B? - Google Patents

DERIVES D'INDOLE CONDENSES UTILISES COMME ANTAGONISTES DES RECEPTEURS 5HT2C et 5HT¿2B? Download PDF

Info

Publication number
WO1994004533A1
WO1994004533A1 PCT/EP1993/002031 EP9302031W WO9404533A1 WO 1994004533 A1 WO1994004533 A1 WO 1994004533A1 EP 9302031 W EP9302031 W EP 9302031W WO 9404533 A1 WO9404533 A1 WO 9404533A1
Authority
WO
WIPO (PCT)
Prior art keywords
indole
methyl
dihydropyrrolo
pyridylcarbamoyl
hydrogen
Prior art date
Application number
PCT/EP1993/002031
Other languages
English (en)
Inventor
Ian Thomson Forbes
Roger Thomas Martin
Peter Ham
Thomas Paul Blackburn
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929217674A external-priority patent/GB9217674D0/en
Priority claimed from GB939306461A external-priority patent/GB9306461D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to AU47046/93A priority Critical patent/AU4704693A/en
Priority to JP6505828A priority patent/JPH08500580A/ja
Priority to EP93917699A priority patent/EP0656003A1/fr
Publication of WO1994004533A1 publication Critical patent/WO1994004533A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • C 1-3 alkyl such as methyl, ethyl, n- and iso- propyl.
  • P represents a quinoline or isoquinoline residue, or a 5- or 6-membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur.
  • Suitable moieties when the ring P is a 5-membered aromatic heterocyclic ring include, for example, isothiazolyl, isoxazolyl, thiadiazolyl and triazolyl.
  • Suitable moieties when the ring P is a 6-membered aromatic heterocyclic ring include, for example, pyridyl, pyrimidyl or pyrazinyl.
  • the urea moiety can be attached at any position of the ring, preferably to the 4-position.
  • the urea moiety can be attached to a carbon or any available nitrogen atom of the ring P, preferably it is attached to a carbon atom.
  • Particularly preferred compounds of formula (I) include:
  • a and R 6 contain the appropriate functional group(s) necessary to form the moiety, -NR 5' CO when coupled, wherein R 5 ' is R 5 as defined in formula (I) or a group convertible thereto, n is as defined in formula (I), and the variables R 1' ,R 2' , R 3' , R 10' , R 11 ' , R 13' , R 14' , R 4' R 5' and R 7' are R 1 , R 2 , R 3 , R 10 , R 11 , R 13 , R 14 R 4 and R 7 respectively, as defined in formula (I), or groups convertible thereto, and thereafter optionally and as necessary and in any appropriate order, converting any R 1' , R 2' , R 3' , R 10' , R 11' , R 13' , R 14' , R 4' , R 5' and R 7' when other than R 1 , R 2 , R 3 , R 10 , R 11 , R 13 , R 14 , R 4
  • R 4' , R 5' , R 7 ', R 13' , and R 14' are as defined in formulae (II) and (III), n is as defined in formula (I), and C and D contain the appropriate functional group(s) necessary to form the indole or indoline ring substituted by R 1' , R 2' , R 3' , R 10' and R 11' as defined in formula (III), and thereafter optionally and as necessary in any appropriate order, converting any R 1' , R 2' , R 3' , R 10' , R 1 1' , R 13' , R 14' , R 4' , R 5' and R 7' when other than R 1 , R 2 , R 3 , R 10 , R 11 , R 13 , R 14 R 4 , R 5 and R 7 , to R 1 , R 2 , R 3 , R 10 , R 1 1 , R 13 , R 14 , R 4 , R 5 and R 7 , interconverting
  • R 5' is as defined above and L is a leaving group.
  • suitable leaving groups L include imidazole, halogen such as chloro or bromo or phenoxy or phenylthio optionally substituted for example with halogen.
  • reaction is suitably carried out in an inert solvent such as toluene at elevated temperature, optionally in the presence of a base.
  • the product of formula (IV) may then be cyclised as in the Fischer synthesis above.
  • Suitable examples of a group R 5' which is convertible to R 5 include
  • R 4 halo and R 7 halo may be introduced by selective halogenation of the ring P or indole/indoline ring respectively using conventional conditions.
  • N-(1-Acetyl-5-indolinyl)-2-chloro-N-trifluoroacetylallylamine (D12) (7.63 g, 22 mmol) was stirred in polyphosphoric acid (38 g) at 140° C for 1.5h. The mixture was cooled, dispersed in water (200 ml) and extracted with ethyl acetate. The extract was filtered through Kieselguhr, dried (Na2S04) and evaporated to give a dark gum (ca. 3g).
  • N-(1-Acetyl-5-indolinyl)-2-chloro-N-methylallylamine (D21) (2.1g, 7.9 mmol) was stirred in polyphosphoric acid (44g) at 140° C for 24h, cooled, dispersed in water (200 ml), and extracted with ethyl acetate. The extract was washed with brine, dried (Na 2 SO 4 ) and evaporated to give a pink solid. Chromatography on silica gel, eluting with 0-20% ethyl acetate in dichloromethane, gave:
  • N-(1,2,3,4-Tetrahydro-6-qumolyl)trifluoroacetamide (D26) (5.64g, 23.1 mmol) and acetyl chloride (2.0 ml, 28 mmol) were stirred in dichloromethane (100 ml) as pyridine (2.25 ml, 28 mmol) was added. The mixture was stirred for 0.5h, when water (100 ml) was added. After vigorous stirring for 0.25 h, it was acidified with 5M hydrochloric acid, and separated. The organic portion was washed with brine, dried (Na 2 SO 4 ), and evaporated, giving the title compound (5.24 g, 79%) as a cream solid.
  • N-(1-Acetyl-1,2,3,4-tetrahydro-6-quinolyl)trifluoroacetamide (D27) (1.85g, 6.5 mmol) was stirred in ethanol (15 ml), and sodium hydroxide (0.52g, 13.0 mmol) was added in water (3ml). The mixture was stirred at ambient temperature for 0.5 h, and then heated to reflux over 0.25 h. After 0.5 h at reflux, the mixture was cooled, acidified with 5M hydrochloric acid, basified with solid sodium carbonate, diluted with water (100 ml), and extracted with chloroform. The extract was dried (Na 2 SO 4 ) and evaporated to give the title compound (1.38g, >100%) as a brown oil containing residual chloroform (NMR).
  • the tide compound was prepared from 5-ethyl-2,3-dihydropyrrolo[2,3-f]indole (D18) and 3-pyridylisocyanate (prepared in situ from nicotinoyl azide) in 58% yield using a procedure similar to that for E1, m.p. 202-203° C.
  • the tide compound was prepared from 2-methyl-4-aminoquinoline, 1,1'-carbonyl diimidazole and 5-methyl-(2,3-dihydropyrrolo[2,3-f]indole) (D6), in 57% yield, m.p.>240° C.
  • the tide compound was prepared by the method of E23, using 5-amino-3-methylsothiazole hydrochloride (0.60g, 4 mmol), CDI (0.71g, 4.4 mmol), triethylamine (0.56ml, 4 mmol) and dihydropyrroloindole (D6) (0.69g, 4 mmol). Triethylamine was added only with the isothiazole hydrochloride.
  • the title compound was prepared from 2-methyl-4-aminopyridine anion (prepared using sodium hydride) 1,1'-carbonyld ⁇ midazole, and 5-methyl-2,3-dihydropyrrolo[2,3-f]indole in dimediylformamide using a procedure similar to that described for Example 5, in 45% yield.
  • the mixture may be compressed to tablets, or filled into hard gelatin capsules.
  • the tablet may be coated by applying a suspension of film former (e.g. HPM cellulose), pigment (e.g. titanium dioxide) and plasticiser (e.g. diethyl phthalate) and drying the film by evaporation of the solvent
  • film former e.g. HPM cellulose
  • pigment e.g. titanium dioxide
  • plasticiser e.g. diethyl phthalate
  • the film coat can comprise 2.0% to 6.0% of the tablet weight preferably about 3.0%.
  • the medicinal compound is dispersed or dissolved in the liquid carrier, with a thickening agent added, if required.
  • the formulation is then enclosed in a soft gelatin capsule by suitable technology.
  • a pharmaceutical composition for parenteral administration may be prepared by combining the following:
  • 5-HT 2C antagonists may have a number of therapeutic indications including the treatment of anxiety, migraine, depression, feeding disorders and obsessive compulsion disorders. (Curzon and Kennett, 1990; Fozard and Gray, 1989) and Alzheimer's Disease (Lawlor, 1989, J. Arch. Gen. Psychiat. Vol. 46 p.542).
  • the cells suspension 400ml was incubated with [ 3 H]-mesulergine (0.5nM) in Tris HCl buffer (pH 7.4) at 37°C for 30 minutes. Non-specific binding was measured in the presence of mianserin (10 -6 M). Ten concentrations of test drug (3 ⁇ 10 -9 to 10 -4 M final concentration) were added in a volume of 50ml. The total assay volume was 500ml. Incubation was stopped by rapid filtration using a Brandel cell harvester and radioactivity measured by scintillation counting. The IC 50 values were determined using a four parameter logistic program (DeLean 1978) and the pK i (the negative logarithm of the inhibition constant) calculated from the Cheng Prusoff equation where:
  • mCPP-induced hypolocomotion was measured in automated locomotion cages of dimensions 56 cm long ⁇ 161 ⁇ 2 cm wide ⁇ 25 cm high and made of black perspex. Two photobeams traversed the wi th of the cages at either end at ground level. Sequential breaking of these beams allowed the measurement of cage transits.
  • mice Male Sprague Dawley rats (200-250g) (Charles River) were housed in groups of six. They were given drugs orally 1h pretest and 40 mins later mCPP (7 mg/kg i.p.). After a further 20 min they were placed in individual automated cages in groups of four under red light in an adjacent room. After 10 min the test was terminated. Reversal of mCPP-induced hypolocomotion was considered as evidence of in vivo central 5-HT 2C receptor antagonist properties.
  • the compound of Example 2 showed a significant increase in social interaction at doses of 10 mg/kg.
  • Rats are trained on a variable interval 30 sec schedule (VT30) to press a lever in order to obtain food reward.
  • the 5 min sessions of the Nl 3 0 schedule alternate with 2-5 min of a schedule (FR5) in which every 5th lever press is followed by presentation of a food pellet paired with a 0.5 sec mild footshock.
  • the total study lasts approximately 30 mins.
  • Rats typically respond with high rates of lever pressing under the VI30 schedule and low response rates under the FR5 'conflict' session.
  • Anxiolytic drugs increase the suppressed response rates of rats in a 'conflict' session.
  • Drugs are administered intraperitoneally or orally to groups of 3-8 rats 30 min before testing.
  • the results are expressed as the percentage increase in the square root of the total number of lever presses in the FR5 'conflict' session. Square root transformation is necessary to normalise the data for statistical analysis using parametric methods.
  • the compound of Example 2 showed a significant increase in responding in the 'conflict' session at dose levels in the range 5 mg/kg p.o.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)

Abstract

Composés de formule (I) ou leur sel, formule dans laquelle P représente un résidu quinoléine ou isoquinoléine, ou bien un composé hétérocyclique aromatique pentagonal ou hexagonal renfermant jusqu'à 3 hétéroatomes choisis parmi azote, oxygène ou soufre; R1 est hydrogène ou alkyle C¿1-6?; R?2, R3, R10 et R11¿ sont indépendamment hydrogène ou alkyle C¿1-6?, ou bien R?10 et R11¿ forment ensemble une liaison, ou encore R?2 et R10 ou R3 et R11¿ forment ensemble une chaîne alkylène C¿2-6; R?4 est hydrogène, alkyle C¿1-6?, halogène, NR?8R9 ou OR12, où R8, R9 et R12¿ sont indépendamment hydrogène ou alkyle C¿1-6; R?5 est hydrogène ou alkyle C¿1-6; R?7 est hydrogène, alkyle C¿1-6, OR?12 ou bien halogène, où R12 est hydrogène ou alkyle C¿1-6?; n vaut 2 ou 3; et les groupes R?13 et R14¿ sont indépendamment hydrogène ou alkyle C¿1-6?. Ces composés sont des antagonistes des récepteurs 5HT2C/5HT2B et sont d'une utilisation potentielle dans le traitement des troubles du système nerveux central, tels que l'anxiété.
PCT/EP1993/002031 1992-08-20 1993-07-29 DERIVES D'INDOLE CONDENSES UTILISES COMME ANTAGONISTES DES RECEPTEURS 5HT2C et 5HT¿2B? WO1994004533A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU47046/93A AU4704693A (en) 1992-08-20 1993-07-29 Condensed indole derivatives as 5HT-2C and 5HT-2B antagonists
JP6505828A JPH08500580A (ja) 1992-08-20 1993-07-29 ５ｈｔ▲下２ｃ▼および５ｈｔ▲下２ｂ▼拮抗薬用縮合インドール誘導体
EP93917699A EP0656003A1 (fr) 1992-08-20 1993-07-29 DERIVES D'INDOLE CONDENSES UTILISES COMME ANTAGONISTES DES RECEPTEURS 5HT2C et 5HT2B

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929217674A GB9217674D0 (en) 1992-08-20 1992-08-20 Novel compounds
GB9217674.2 1992-08-20
GB9306461.6 1993-03-29
GB939306461A GB9306461D0 (en) 1993-03-29 1993-03-29 Novel compounds

Publications (1)

Publication Number Publication Date
WO1994004533A1 true WO1994004533A1 (fr) 1994-03-03

Family

ID=26301461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/002031 WO1994004533A1 (fr) 1992-08-20 1993-07-29 DERIVES D'INDOLE CONDENSES UTILISES COMME ANTAGONISTES DES RECEPTEURS 5HT2C et 5HT¿2B?

Country Status (13)

Country Link
EP (1) EP0656003A1 (fr)
JP (1) JPH08500580A (fr)
CN (1) CN1086819A (fr)
AP (1) AP9300560A0 (fr)
AU (1) AU4704693A (fr)
CA (1) CA2142721A1 (fr)
IL (1) IL106737A0 (fr)
MA (1) MA22955A1 (fr)
MX (1) MX9305037A (fr)
NZ (1) NZ254785A (fr)
SI (1) SI9300438A (fr)
TW (1) TW248557B (fr)
WO (1) WO1994004533A1 (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022871A1 (fr) * 1993-03-29 1994-10-13 Smithkline Beecham Plc DERIVES THIENO-INDOLIQUES UTILISES COMME ANTAGONISTES DE 5HT2c ET DE 5HT2b
WO1995001976A1 (fr) * 1993-07-06 1995-01-19 Smithkline Beecham Plc Derives indoliniques utilises comme antagonistes de 5ht¿2c?
WO1995021844A1 (fr) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Indoles condenses a titre d'antagonistes des recepteurs de 5ht¿2b?
WO1995029177A1 (fr) * 1994-04-23 1995-11-02 Smithkline Beecham P.L.C. Derives tricycliques antagonistes de 5ht2c et de 5ht2b
WO1996011929A1 (fr) * 1994-10-12 1996-04-25 Smithkline Beecham Plc Derives biheteroaryl-carbonyles et carboxamides possedant une activite antagoniste de 5ht 2c/2b
WO1996011930A1 (fr) * 1994-10-18 1996-04-25 Smithkline Beecham P.L.C. Derives de pyridinyluree actifs dans le traitement des troubles du systeme nerveux central
WO1996023783A1 (fr) * 1995-02-02 1996-08-08 Smithkline Beecham Plc Derives d'indole utilises comme antagoniste du recepteur de 5-ht
WO1996023769A2 (fr) * 1995-02-02 1996-08-08 Smithkline Beecham Plc Composes heterocycliques possedant une activite antagoniste vis-a-vis du recepteur de 5ht¿2c?
WO1997008167A1 (fr) * 1995-08-26 1997-03-06 Smithkline Beecham P.L.C. Antagonistes des recepteurs 5ht2c et 5ht¿2b?
WO1997037989A1 (fr) * 1996-04-04 1997-10-16 Smithkline Beecham Plc Derives indoles en tant qu'antagonistes du recepteur de 5-ht
WO1997048699A1 (fr) * 1996-06-20 1997-12-24 Smithkline Beecham Plc Derives de l'indoline utiles comme antagonistes des recepteurs 5ht-2c
WO1997048700A1 (fr) * 1996-06-20 1997-12-24 Smithkline Beecham Plc Derives de l'indoline utiles comme antagonistes des recepteurs 5ht-2c
WO1998024785A1 (fr) * 1996-12-02 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Derives d'indole-uree presentant des proprietes d'antagonistes de 5-ht
WO1999025709A1 (fr) * 1997-11-18 1999-05-27 Smithkline Beecham P.L.C. Derives d'isoquinoline et leur utilisation therapeutique
EP1348704A1 (fr) * 2002-03-27 2003-10-01 Les Laboratoires Servier Dérivés d'indole possédant des propriétés antagonistes 5-HT2C, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2004057338A1 (fr) * 2002-12-23 2004-07-08 Bayer Healthcare Ag Diagnostic et traitement de maladies associees au recepteur 2b (5-hteb) de 5-hydroxytryptamine (serotonine)
WO2004081010A1 (fr) * 2003-03-11 2004-09-23 Glaxo Group Limited Composes ayant une activite au niveau du recepteur 5ht2c et leurs utilisations
KR100470691B1 (ko) * 2000-04-13 2005-03-07 르 라보레또레 쎄르비에르 시클로부타인돌카르복사미드 화합물, 이의 제조 방법 및이를 함유하는 약제 조성물
EP2036564A1 (fr) 1999-12-06 2009-03-18 H.Lundbeck A/S Combinaison d'un inhibiteur du recaptage de la serotonine et d'un antagoniste, d'un agoniste inverse ou d'un agoniste partiel de 5-ht
WO2014049153A1 (fr) * 2012-09-28 2014-04-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur 5-h2b pour utilisation dans la prévention ou le traitement de la spasticité
WO2022006365A3 (fr) * 2020-07-02 2022-02-10 Purdue Research Foundation Composés contenant de la tétrahydro-3h-pyrazolo quinolone et de la tétrahydro-3h-pyrrolo[3,2-f]-quinoléine et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005170A1 (fr) * 1990-09-13 1992-04-02 Beecham Group Plc Urees d'indole utilisees comme antagonistes de recepteur de 5-ht

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005170A1 (fr) * 1990-09-13 1992-04-02 Beecham Group Plc Urees d'indole utilisees comme antagonistes de recepteur de 5-ht

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022871A1 (fr) * 1993-03-29 1994-10-13 Smithkline Beecham Plc DERIVES THIENO-INDOLIQUES UTILISES COMME ANTAGONISTES DE 5HT2c ET DE 5HT2b
WO1995001976A1 (fr) * 1993-07-06 1995-01-19 Smithkline Beecham Plc Derives indoliniques utilises comme antagonistes de 5ht¿2c?
US5834494A (en) * 1993-07-06 1998-11-10 Smithkline Beecham P.L.C. Pyridylcarbamoyl Indolines
WO1995021844A1 (fr) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Indoles condenses a titre d'antagonistes des recepteurs de 5ht¿2b?
WO1995029177A1 (fr) * 1994-04-23 1995-11-02 Smithkline Beecham P.L.C. Derives tricycliques antagonistes de 5ht2c et de 5ht2b
WO1996011929A1 (fr) * 1994-10-12 1996-04-25 Smithkline Beecham Plc Derives biheteroaryl-carbonyles et carboxamides possedant une activite antagoniste de 5ht 2c/2b
WO1996011930A1 (fr) * 1994-10-18 1996-04-25 Smithkline Beecham P.L.C. Derives de pyridinyluree actifs dans le traitement des troubles du systeme nerveux central
US5866586A (en) * 1994-10-18 1999-02-02 Smithkline Beecham P.L.C. CNS-active pyridinylurea derivatives
WO1996023769A3 (fr) * 1995-02-02 1996-10-24 Smithkline Beecham Plc Composes heterocycliques possedant une activite antagoniste vis-a-vis du recepteur de 5ht¿2c?
US6235758B1 (en) * 1995-02-02 2001-05-22 Smithkline Beecham P.L.C. Indole derivatives as 5-HT receptor antagonist
US6638953B2 (en) 1995-02-02 2003-10-28 Smithkline Beecham P.L.C. Indole derivatives as 5-HT receptor antagonist
US5990133A (en) * 1995-02-02 1999-11-23 Smithkline Beecham P.L.C. Indole derivatives as 5-HT receptor antagonist
US5972937A (en) * 1995-02-02 1999-10-26 Smithkline Beecham P.L.C. Heterocyclic compounds possessing 5HT2C receptor antagonist activity
WO1996023783A1 (fr) * 1995-02-02 1996-08-08 Smithkline Beecham Plc Derives d'indole utilises comme antagoniste du recepteur de 5-ht
AP657A (en) * 1995-02-02 1998-08-06 Smithkline Beecham Plc Indole derivatives as 5-HT receptor antagonist.
WO1996023769A2 (fr) * 1995-02-02 1996-08-08 Smithkline Beecham Plc Composes heterocycliques possedant une activite antagoniste vis-a-vis du recepteur de 5ht¿2c?
WO1997008167A1 (fr) * 1995-08-26 1997-03-06 Smithkline Beecham P.L.C. Antagonistes des recepteurs 5ht2c et 5ht¿2b?
US6028085A (en) * 1996-04-04 2000-02-22 Smithkline Beecham Plc Indole derivatives as 5-HT receptor antagonist
WO1997037989A1 (fr) * 1996-04-04 1997-10-16 Smithkline Beecham Plc Derives indoles en tant qu'antagonistes du recepteur de 5-ht
US6369060B1 (en) 1996-06-20 2002-04-09 Smithkline Beecham P.L.C. Indoline derivatives useful as 5-HT-2C receptor antagonists
WO1997048700A1 (fr) * 1996-06-20 1997-12-24 Smithkline Beecham Plc Derives de l'indoline utiles comme antagonistes des recepteurs 5ht-2c
US6313145B1 (en) 1996-06-20 2001-11-06 Smithkline Beecham P.L.C. Indoline derivatives useful as 5-HT-2C receptor antagonists
WO1997048699A1 (fr) * 1996-06-20 1997-12-24 Smithkline Beecham Plc Derives de l'indoline utiles comme antagonistes des recepteurs 5ht-2c
WO1998024785A1 (fr) * 1996-12-02 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Derives d'indole-uree presentant des proprietes d'antagonistes de 5-ht
US6274594B1 (en) 1997-11-18 2001-08-14 Smithkline Beecham P.L.C. Isoquinoline derivatives and their therapeutical use
WO1999025709A1 (fr) * 1997-11-18 1999-05-27 Smithkline Beecham P.L.C. Derives d'isoquinoline et leur utilisation therapeutique
EP2036564A1 (fr) 1999-12-06 2009-03-18 H.Lundbeck A/S Combinaison d'un inhibiteur du recaptage de la serotonine et d'un antagoniste, d'un agoniste inverse ou d'un agoniste partiel de 5-ht
KR100470691B1 (ko) * 2000-04-13 2005-03-07 르 라보레또레 쎄르비에르 시클로부타인돌카르복사미드 화합물, 이의 제조 방법 및이를 함유하는 약제 조성물
FR2837823A1 (fr) * 2002-03-27 2003-10-03 Servier Lab Nouveaux derives d'indoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003203287B2 (en) * 2002-03-27 2008-08-28 Les Laboratoires Servier New indoline compounds, a process for their preparation and pharmaceutical compositions containing them
EP1348704A1 (fr) * 2002-03-27 2003-10-01 Les Laboratoires Servier Dérivés d'indole possédant des propriétés antagonistes 5-HT2C, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2004057338A1 (fr) * 2002-12-23 2004-07-08 Bayer Healthcare Ag Diagnostic et traitement de maladies associees au recepteur 2b (5-hteb) de 5-hydroxytryptamine (serotonine)
WO2004081010A1 (fr) * 2003-03-11 2004-09-23 Glaxo Group Limited Composes ayant une activite au niveau du recepteur 5ht2c et leurs utilisations
WO2014049153A1 (fr) * 2012-09-28 2014-04-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur 5-h2b pour utilisation dans la prévention ou le traitement de la spasticité
WO2022006365A3 (fr) * 2020-07-02 2022-02-10 Purdue Research Foundation Composés contenant de la tétrahydro-3h-pyrazolo quinolone et de la tétrahydro-3h-pyrrolo[3,2-f]-quinoléine et leurs utilisations

Also Published As

Publication number Publication date
TW248557B (fr) 1995-06-01
CA2142721A1 (fr) 1994-03-03
JPH08500580A (ja) 1996-01-23
SI9300438A (en) 1994-03-31
CN1086819A (zh) 1994-05-18
MA22955A1 (fr) 1994-04-01
NZ254785A (en) 1995-09-26
AU4704693A (en) 1994-03-15
EP0656003A1 (fr) 1995-06-07
IL106737A0 (en) 1994-05-30
AP9300560A0 (en) 1995-02-19
MX9305037A (es) 1994-03-31

Similar Documents

Publication Publication Date Title
WO1994004533A1 (fr) DERIVES D'INDOLE CONDENSES UTILISES COMME ANTAGONISTES DES RECEPTEURS 5HT2C et 5HT¿2B?
DE60125373T2 (de) Aminopiperidin chinoline und ihre azaisosteren analoga mit antibakterieller wirkung
DE69221059T2 (de) Indolderivate und antiulcerose Zubereitungen
US5089496A (en) Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US6849640B2 (en) Therapeutic 1H-pyrido [4,3-b] indoles
FI96768B (fi) Menetelmä valmistaa farmakologisesti arvokasta bentso/5,6/sykloheptapyridiiniä
ES2272667T3 (es) Indol-5-il esteres del acido bencenosulfonico como antagonistas de receptor 5-ht6.
US5589476A (en) Imidazol-4-ylpiperidine derivatives, their preparation and their application in therapeutics
DD259190A5 (de) Verfahren zur herstellung von substituierten bruecken-diazabic ycloalkyl-chinolon-carbonsaeuren
WO1993018028A1 (fr) Derives d'indole utilises comme antagonistes de 5ht¿1c?
WO1996011929A1 (fr) Derives biheteroaryl-carbonyles et carboxamides possedant une activite antagoniste de 5ht 2c/2b
EP0705832B1 (fr) Modulateurs serotonergiques
DE60309852T2 (de) Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden
US5296478A (en) 1-substituted oxindoles as cognition enhancers
HU205354B (en) Process for producing new tricyclic benzimidazoles and pharmaceutical compositions comprising same
NZ238141A (en) 1,2,3,4,4a,10b-hexahydro-6-(sulphonamidophenyl)benzo(c)(1,6)naphthyridine derivatives, preparation and pharmaceutical compositions thereof
WO1996011930A1 (fr) Derives de pyridinyluree actifs dans le traitement des troubles du systeme nerveux central
US5563147A (en) Serotonerbic tetrahydropyridoindoles
JPH08502273A (ja) ５−ｈｔ▲下４▼レセプターアンタゴニスト用複素環式エステルまたはアミド
WO2003006466A1 (fr) Hexahydroazepino (4, 5-g) indoles et indolines, ligands du recepteur 5-ht
HU220874B1 (en) Imidazopyridine-azolidinones, process for producing them, the use thereof and pharmaceutical compositions containing them
EP0757687A1 (fr) Derives tricycliques antagonistes de 5ht2c et de 5ht2b
EP0743946A1 (fr) Indoles condenses a titre d'antagonistes des recepteurs de 5ht 2b?
KR0173451B1 (ko) 피리미도인돌 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
US5665726A (en) Benzo[5,6]cycloheptapyridines, compositions and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 254785

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1995 387731

Country of ref document: US

Date of ref document: 19950215

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2142721

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993917699

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993917699

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1993917699

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993917699

Country of ref document: EP